In this blog we interview Debs Watkins, a Research Consultant at YHEC. We find out how she got into this role, what her day-to-day work looks like, and what she enjoys most about being part of YHEC.
Securing reimbursement for therapies targeting rare diseases relies on a compelling demonstration of their value. However, the unique challenges inherent in rare disease research often make robust evidence generation an uphill battle. In this blog, Stuart Mealing offers insightful perspectives on the hurdles and strategies for effectively showcasing the value of these vital interventions.
Drug development and market access is often challenging for rare disease therapies. There are numerous obstacles in the field, such as small and diverse patient populations, which means there is often limited evidence available. YHEC's Andria Joseph explores some of the challenges in rare diseases, specifically relating to patient-reported outcomes, and provides potential solutions for overcoming these.
While no two models are ever the same, this model provides a good illustration of what a standard YHEC economic model looks like. The model is user-friendly and straightforward to navigate, allowing users to easily run a cost-effectiveness analysis. This model is developed in Microsoft Excel, which is the most frequently used software tool for developing health economic models.
In this blog we interview Mick Arber, a Senior Information Specialist at YHEC. We find out how he got into this role, what his day-to-day work looks like, and what he enjoys most about being part of YHEC.
This budget impact model was developed using R Shiny. This type of model combines the power of the R statistical software with a user-friendly, point-and-click interface, so you don’t need to interact with any R code. Ideal for leveraging advanced capabilities while maintaining ease of use, R Shiny models are accessible via any web browser.
Reducing health inequity is a challenging global issue. In this blog, YHEC’s Robert Malcolm shares his insights on the importance of incorporating health equity into economic evaluation, how we can do this, and what he hopes to see in the future in this area.
